For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

We use cookies to make our site as useful as possible.

Our Cookie Policy explains how you can opt-out of the cookies we use.

If you continue without changing your cookie settings, we'll assume you’re happy with this.

Continue Continue

United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Diagnostic & Therapeutic Solutions
    Custom solutions & partnerships

    Custom antibody development and commercial partnerships to advance your diagnostic and therapeutic discovery.

    Create custom solutions with us

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Supporting our customers and employees during the COVID-19 pandemic. Read more

Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway

Related

  • PD-L1/ PD-1 products
    • PD-L1 [28-8] RabMAb® antibody
      • PD1 monoclonal antibody
        • PD-L1 trial panel
          • Compare PD-L1 clones
          • Identify T cells with FOXP3 antibody
            • T cell cytokine ELISA kits and reagents
                • Immuno-oncology resources
                  • Immune checkpoint pathway
                    • Immune cell markers
                      • Effector T cell markers
                        • Hallmarks of cancer
                            • Protocols
                              • Flow cytometry immunophenotyping
                                • PD-L1 [28-8] RabMAb® protocols for automated IHC
                                    • Events
                                      • New Directions in Immuno-oncology: Response and Resistance conference (February 2021)

                                        ​​Read about the PD-1/PD-L1 pathway, its function in cancer, and how it is being used in immunotherapy.

                                        ​​Overview 

                                        • Immune checkpoint inhibitors
                                        • What is the PD-1/PD-L1 pathway?
                                        • The role of PD-1/PD-L1 in cancer
                                        • Using PD-1/PD-L1 and immunotherapy
                                          • Combination immunotherapy
                                          • Adoptive T cell therapy
                                        • References

                                        ​Immune checkpoint inhibitors

                                        The immune system plays an important role in protecting us from disease and clearing the body’s own unhealthy and ailing cells. The T cells of the immune system have a capacity to selectively recognize and kill pathogens or unhealthy cells, including cancer cells, by orchestrating a coordinated immune response including innate and adaptive responses.

                                        Many checkpoints ensure the immune system cells do not mistakenly destroy healthy cells during an immune response (known as an autoimmune reaction). Cancer cells can exploit these immune checkpoints as a way to evade immune detection and elimination.

                                        By blocking immune checkpoint proteins, including PD-1, PD-L1 and CTLA-4, with monoclonal antibodies, the immune system can overcome cancer’s ability to resist the immune responses and stimulate the body's own mechanisms to remain effective in its defenses against cancer.

                                        What is the PD-1/PD-L1 pathway?

                                        The PD-1 (programmed cell death-1) receptor is expressed on the surface of activated T cells. Its ligands, PD-L1 and PD-L2, are expressed on the surface of dendritic cells or macrophages. PD-1 and PD-L1/PD-L2 belong to the family of immune checkpoint proteins that act as co-inhibitory factors that can halt or limit the development of the T cell response. The PD-1/PD-L1 interaction ensures that the immune system is activated only at the appropriate time in order to minimize the possibility of chronic autoimmune inflammation.

                                        The role of PD-1/PD-L1 in cancer

                                        Under normal conditions, the immune system performs a series of steps which lead to an anticancer immune response and cancer cell death, known as the cancer immunity cycle1:

                                        1. Tumor cells produce mutated antigens that are captured by dendritic cells
                                        2. The dendritic cells prime T cell with tumor antigen and stimulate the activation of cytotoxic T cells
                                        3. Activated T cells then travel to the tumor and infiltrate the tumor environment
                                        4. The activated T cells recognize and bind to the cancer cells
                                        5. The bound effector T cells release cytotoxins, which induce apoptosis in their target cancer cells

                                        The PD-1/PD-L1 pathway represents an adaptive immune resistance mechanism exerted by tumor cells in response to endogenous immune anti-tumor activity. PD-L1 is overexpressed on tumor cells or on non-transformed cells in the tumor microenvironment2. PD-L1 expressed on the tumor cells binds to PD-1 receptors on the activated T cells, which leads to the inhibition of the cytotoxic T cells. These deactivated T cells remain inhibited in the tumor microenvironment.

                                        Using PD-1/PD-L1 and immunotherapy

                                        Monoclonal antibody therapies against PD-1 and PD-L1 are being routinely used including: 

                                        • Nivolumab, an anti-PD-1 drug developed by Bristol-Myers Squibb, which is approved for previously treated metastatic melanoma and squamous non-small cell lung cancer. 
                                        • Pembrolizumab, developed by Merck is approved for previously treated metastatic melanoma.

                                        There are several other immunotherapy options being used or in development.

                                        Combination immunotherapy

                                        The efficiency of the immune checkpoint blockade with monoclonal antibodies in cancer treatment is remarkable, but not all patients respond to a single therapy. To enhance and broaden the anti-tumor activity of immune checkpoint inhibition the next step is combining agents with synergistic mechanisms of action. An example of this is the success of the combination of PD-1/PD-L1 inhibition blockage with complementary checkpoint inhibitor CTLA-4 in melanoma and non-small cell lung cancer3.

                                        Adoptive T cell therapy

                                        Adoptive T cell therapy involves first isolating tumor-specific T cells from patients and then expanding these ex vivo. The tumor-specific T cells can then be infused into patients to give their immune system the ability to overwhelm remaining tumor cells. 

                                        T cells can be harvested either from the patient's tumor (tumor-infiltrating lymphocytes, TILs) or peripheral blood (peripheral blood lymphocytes, PBLs). Tumor specificity must be induced in PBLs either through antigen-specific expansion or genetic engineering4. After expansion in culture, tumor-specific T cells can be reinfused into the cancer patient.

                                        Another type of adoptive cell therapy is CAR T cell therapy, where T cells are engineered to express chimeric antigen receptors (CARs) that recognize cancer-specific antigens. This means researchers can prime the cells to recognize and kill tumor cells that would otherwise escape immune detection5.

                                        CAR-T cells and T cells with engineered tumor-specific TCRs show anti-tumor activity in some solid tumors and hematological malignances1.

                                        References

                                        1. Chen, D. and Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).

                                        2. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12, 252–264 (2012).

                                        3. Ott, P.A., et al. (2017). Combination immunotherapy: a road map. J Immunother Cancer, 5:16 (2017).

                                        4. Perica, K., et al. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J, 6: e0004 (2015).

                                        5. Grupp, S., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med, 368, 1509-1518 (2013).

                                        Alexa Fluor® is a registered trademark of Life Technologies. Alexa Fluor® dye conjugates contain(s) technology licensed to Abcam by Life Technologies.





                                        ​​

                                        ​




                                        Get resources and offers direct to your inbox Sign up
                                        A-Z by research area
                                        • Cancer
                                        • Cardiovascular
                                        • Cell biology
                                        • Developmental biology
                                        • Epigenetics & Nuclear signaling
                                        • Immunology
                                        • Metabolism
                                        • Microbiology
                                        • Neuroscience
                                        • Signal transduction
                                        • Stem cells
                                        A-Z by product type
                                        • Primary antibodies
                                        • Secondary antibodies
                                        • Biochemicals
                                        • Isotype controls
                                        • Flow cytometry multi-color selector
                                        • Kits
                                        • Loading controls
                                        • Lysates
                                        • Peptides
                                        • Proteins
                                        • Slides
                                        • Tags and cell markers
                                        • Tools & Reagents
                                        Help & support
                                        • Support
                                        • Make an Inquiry
                                        • Protocols & troubleshooting
                                        • Placing an order
                                        • RabMAb products
                                        • Biochemical product FAQs
                                        • Training
                                        • Browse by Target
                                        Company
                                        • Corporate site
                                        • Investor relations
                                        • Company news
                                        • Careers
                                        • About us
                                        • Blog
                                        Events
                                        • Tradeshows
                                        • Conferences
                                        International websites
                                        • abcam.cn
                                        • abcam.co.jp

                                        Join with us

                                        • LinkedIn
                                        • facebook
                                        • Twitter
                                        • YouTube
                                        • Terms of sale
                                        • Website terms of use
                                        • Cookie policy
                                        • Privacy policy
                                        • Legal
                                        • Modern slavery statement
                                        © 1998-2021 Abcam plc. All rights reserved.